Pomalidomide as an Immune-enhancing Agent for the Control of HIV
Status:
RECRUITING
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of pomalidomide in HIV-1-infected individuals on ART and to determine the impact of pomalidomide on virological control in people living with HIV during an analytical treatment interruption.